المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO

المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Peters , S , Planchard , D , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Oncogene-addicted metastatic non-small-cell lung cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 339-357 . https://doi.org/10.1016Test/j.annonc.2022.12.009

مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, TYROSINE KINASE INHIBITORS, PROGRESSION-FREE SURVIVAL, RESPONSE EVALUATION CRITERIA, FACTOR RECEPTOR MUTATIONS, OPEN-LABEL, 1ST-LINE TREATMENT, SINGLE-ARM, TREATMENT-NAIVE, EGFR MUTATIONS, ADVANCED NSCLC

وصف الملف: application/pdf

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test

الإتاحة: https://doi.org/10.1016Test/j.annonc.2022.12.009
https://cris.maastrichtuniversity.nl/en/publications/a6c20759-e209-411f-b9b7-789fc32e2f64Test
https://cris.maastrichtuniversity.nl/ws/files/192165782/Hendriks-2023-Oncogene-addicted-metastatic-non-small.pdfTest

المؤلفون: Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Planchard, D., Peters, S., Smit, E. F., Solomon, B. J., Veronesi, G., Reck, M., Guidelines Committee, ESMO

المصدر: Hendriks , L E , Kerr , K M , Menis , J , Mok , T S , Nestle , U , Passaro , A , Planchard , D , Peters , S , Smit , E F , Solomon , B J , Veronesi , G , Reck , M , ESMO Guidelines Committee & Guidelines Committee , ESMO 2023 , ' Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ' , Annals of Oncology , vol. 34 , no. 4 , pp. 358-376 . https://doi.org/10.1016Test/j.annonc.2022.12.013

مصطلحات موضوعية: ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy, immunotherapy, RANDOMIZED PHASE-III, QUALITY-OF-LIFE, PACLITAXEL DOUBLET CHEMOTHERAPY, RESPONSE EVALUATION CRITERIA, PLATINUM-BASED CHEMOTHERAPY, PEMETREXED PLUS CISPLATIN, SPECIFIED FINAL ANALYSIS, INDIVIDUAL PATIENT DATA, ELDERLY-PATIENTS, 2ND-LINE TREATMENT

وصف الملف: application/pdf

العلاقة: https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test

الإتاحة: https://doi.org/10.1016Test/j.annonc.2022.12.013
https://cris.maastrichtuniversity.nl/en/publications/7f71c7db-b119-4345-a38e-5b383cefe585Test
https://cris.maastrichtuniversity.nl/ws/files/192165470/Hendriks-2023-Non-oncogene-addicted-metastatic-non.pdfTest

المؤلفون: Drilon, A., Camidge, D. R., Lin, J. J., Kim, S. W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., Lee, K. H., Popat, S., Springfeld, C., Nagasaka, M., Felip, E., Yang, N., Velcheti, V., Lu, S., Kao, S., Dooms, C., Krebs, Matthew G, Yao, W., Beg, M. S., Hu, X., Moro-Sibilot, D., Cheema, P., Stopatschinskaja, S., Mehta, M., Trone, D., Graber, A., Sims, G., Yuan, Y., Cho, B. C.

المساهمون: Christie NHS Foundation Trust, Manchester

العلاقة: https://dx.doi.org/10.1056/NEJMoa2302299Test; Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2024 Jan 11;390(2):118-31. PubMed PMID: 38197815. Epub 2024/01/10.; http://hdl.handle.net/10541/626874Test; New England Journal of Medicine

الإتاحة: https://doi.org/10.1056/NEJMoa2302299Test
http://hdl.handle.net/10541/626874Test

المؤلفون: Chazan, G., Franchini, F., Alexander, M., Banerjee, S., Mileshkin, L., Blinman, P., Zielinski, R., Karikios, D., Pavlakis, N., Peters, S., Lordick, F., Ball, D., Wright, G., IJzerman, M., Solomon, B. J.

المصدر: Chazan , G , Franchini , F , Alexander , M , Banerjee , S , Mileshkin , L , Blinman , P , Zielinski , R , Karikios , D , Pavlakis , N , Peters , S , Lordick , F , Ball , D , Wright , G , IJzerman , M & Solomon , B J 2021 , ' Impact of COVID-19 on cancer service delivery : a follow-up international survey of oncology clinicians ' , ESMO Open , vol. 6 , no. 5 , 100224 . https://doi.org/10.1016Test/j.esmoop.2021.100224

مصطلحات موضوعية: /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being, SDG 3 - Good Health and Well-being

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1016Test/j.esmoop.2021.100224
https://pure.eur.nl/en/publications/7bd7e9bd-0caf-45a9-981d-19f3d422a9b2Test
https://pure.eur.nl/ws/files/54225545/1_s2.0_S205970292100185X_main.pdfTest
http://www.scopus.com/inward/record.url?scp=85115362631&partnerID=8YFLogxKTest

المؤلفون: Lin, J. J., Drilon, A. E., Cho, B. C., Felip, E., De Langen, A., Yang, N., Kim, S. W., Lu, S., Kao, S. C. H., Velcheti, V., Moro Sibilot, D. L., Solomon, B. J., Dziadziuszko, R., Krebs, Matthew G, Cheema, P. K., Dooms, C. A., Stopatschinskaja, S., Trone, D., Ades, F., Camidge, D. R.

المساهمون: Massachusetts General Hospital Cancer Center, Boston, MA

العلاقة: https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.9017Test; Lin JJ, Drilon AE, Cho BC, Felip E, De Langen A, Yang N, et al. Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion- positive ( ROS1 +) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003685.; http://hdl.handle.net/10541/626656Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2023.41.16_suppl.9017Test
http://hdl.handle.net/10541/626656Test

المؤلفون: de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Yoneshima, Y., Kim, S. W., Linardou, H., Novello, S., van der Wekken, A. J., Chen, Y., Peters, S., Felip, E., Solomon, B. J., Ramalingam, S. S., Dooms, C., Lindsay, Colin R, Ferreira, C. G., Blais, N., Obiozor, C. C., Wang, Y., Mehta, B., Varrieur, T., Ngarmchamnanrith, G., Stollenwerk, B., Waterhouse, D., Paz-Ares, L.

المساهمون: Netherlands Cancer Institute, Amsterdam, Netherlands

العلاقة: https://dx.doi.org/10.1016/s0140-6736Test(23)00221-0; de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023 Mar 4;401(10378):733-46. PubMed PMID: 36764316. Epub 2023/02/11. eng.; http://hdl.handle.net/10541/626058Test; Lancet

الإتاحة: https://doi.org/10.1016/s0140-6736Test(23)00221-0
http://hdl.handle.net/10541/626058Test

المؤلفون: Rischin, D., Mehanna, H., Young, R. J., Bressel, M., Dunn, Janet A., Corry, J., Soni, P., Fulton-Lieuw, T., Iqbal, G., Kenny, L., Porceddu, S., Wratten, C., Robinson, M., Solomon, B. J., HASH(0x5651c987e5b8), HASH(0x5651c97cfdb0)

مصطلحات موضوعية: RC0254, Oncology, Hematology

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5909d6de3203da2e661e11560af63455Test
http://wrap.warwick.ac.uk/167179/1/WRAP-Prognostic-stratification-HPV-oropharyngeal-cancer-CD103-immune-patients-TROG-1201-2022.pdfTest

المؤلفون: Solomon, B. J., Bauer, T. M., Felip, E., Liu, G., Mazieres, J., De Marinis, F., Goto, Y., Kim, D. W., Laktionov, K. K., Blackhall, Fiona H, Dall'O, E., Polli, A., Toffalorio, F., Mok, T. S. K.

المساهمون: Department of Medical Oncology and Research Division, Peter MacCallum Cancer Centre & Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

العلاقة: https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.9069Test; Solomon BJ, Bauer TM, Felip E, Liu G, Mazieres J, De Marinis F, et al. Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302255.; http://hdl.handle.net/10541/625820Test; Journal of Clinical Oncology

الإتاحة: https://doi.org/10.1200/JCO.2022.40.16_suppl.9069Test
http://hdl.handle.net/10541/625820Test

المؤلفون: Shaw, A. T., Bauer, T. M., De Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D. -W., Mok, T., Polli, A., Thurm, H., Calella, A. M., Peltz, G., Solomon, B. J., Soto Parra, H.

المصدر: CROWN Trial Investigators & Blackhall, F 2020, ' First-line lorlatinib or crizotinib in advanced alk-positive lung cancer ', New England Journal Of Medicine, vol. 383, no. 21, pp. 2018-2029 . https://doi.org/10.1056/NEJMoa2027187Test

مصطلحات موضوعية: Male, Alectinib, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung/drug therapy, medicine.medical_treatment, 030204 cardiovascular system & hematology, Macrocyclic, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, hemic and lymphatic diseases, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, 030212 general & internal medicine, Non-Small-Cell Lung, Manchester Cancer Research Centre, General Medicine, Middle Aged, Crizotinib/adverse effects, Intention to Treat Analysis, Female, Hyperlipidemias/chemically induced, medicine.drug, Adult, Lactams, Macrocyclic/adverse effects, Lactams, Lactams, Macrocyclic, Anaplastic Lymphoma Kinase/antagonists & inhibitors, Antineoplastic Agents, Hyperlipidemias, 03 medical and health sciences, Crizotinib, ROS1, medicine, Humans, Lung Neoplasms/drug therapy, Lung cancer, Aged, Chemotherapy, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Carcinoma, Cancer, Antineoplastic Agents/adverse effects, medicine.disease, Survival Analysis, Lorlatinib, Mutation, Cancer research, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e198e069fced42b320415b72e5031c98Test
https://doi.org/10.1056/nejmoa2027187Test

المؤلفون: Rischin, D., Mehanna, H., Porceddu, S., Wratten, C., Robinson, M., Solomon, B. J., Young, R. J., Bressel, M., Dunn, J., Corry, J., Soni, P., Fulton-Lieuw, T., Iqbal, G., Kenny, L.

المساهمون: The University of Newcastle. College of Health, Medicine & Wellbeing, School of Medicine and Public Health

مصطلحات موضوعية: head and neck cancer, oropharyngeal cancer, human papillomavirus, CD103, cetuximab, cisplatin, SDG 3, Sustainable Development Goals

العلاقة: Annals of Oncology Vol. 33, Issue 8, p. 804-813; http://hdl.handle.net/1959.13/1486122Test; uon:51782

الإتاحة: http://hdl.handle.net/1959.13/1486122Test